These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25854825)

  • 21. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.
    Stevens GL; Dawson G; Zummo J
    Early Interv Psychiatry; 2016 Oct; 10(5):365-77. PubMed ID: 26403538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral Antipsychotic Versus Long-Acting Injections Antipsychotic in Schizophrenia Spectrum Disorder: a Mirror Analysis in a Real-World Clinical Setting.
    Poloni N; Ielmini M; Caselli I; Lucca G; Gasparini A; Gasparini A; Lorenzoli G; Callegari C
    Psychopharmacol Bull; 2019 Jun; 49(2):17-27. PubMed ID: 31308579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient outcomes within schizophrenia treatment: a look at the role of long-acting injectable antipsychotics.
    Bera RB
    J Clin Psychiatry; 2014; 75 Suppl 2():30-3. PubMed ID: 24919169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Use of slow-release injections to administer antipsychotic drugs].
    Høiseth G; Bentsen H
    Tidsskr Nor Laegeforen; 2012 Feb; 132(3):301-3. PubMed ID: 22314741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-acting injectable (depot) antipsychotics and changing treatment philosophy: possible contribution to integrative care and personal recovery of schizophrenia.
    Jakovljević M
    Psychiatr Danub; 2014 Dec; 26(4):304-7. PubMed ID: 25377363
    [No Abstract]   [Full Text] [Related]  

  • 27. Improving Long-Term Outcomes in Patients With Schizophrenia: What Is the Evidence for Long-Acting Injectable Antipsychotics?
    Perkins DO
    J Clin Psychiatry; 2017; 78(9):e1431. PubMed ID: 29345879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipsychotic long-acting injections: mind the gap.
    Patel MX; Taylor M; David AS
    Br J Psychiatry Suppl; 2009 Nov; 52():S1-4. PubMed ID: 19880911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple Long-Acting Injectable Antipsychotics for Treatment-Resistant Schizophrenia: Case Report.
    Scangos KW; Caton M; Newman WJ
    J Clin Psychopharmacol; 2016 Jun; 36(3):283-5. PubMed ID: 27035492
    [No Abstract]   [Full Text] [Related]  

  • 30. Examining patient outcomes of receiving long-acting injectable antipsychotics.
    Lu L; Ren D; Mullick P; Lee H
    Perspect Psychiatr Care; 2020 Jan; 56(1):14-19. PubMed ID: 30746711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-acting injectable aripiprazole (Abilify Maintena) for schizophrenia.
    Med Lett Drugs Ther; 2013 Apr; 55(1415):34-6. PubMed ID: 23836344
    [No Abstract]   [Full Text] [Related]  

  • 32. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral.
    Offord S; Wong B; Mirski D; Baker RA; Lin J
    J Med Econ; 2013; 16(2):231-9. PubMed ID: 23163287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of long acting injectable antipsychotics (LAI) over oral formulations.
    Uvais NA
    Asian J Psychiatr; 2018 Feb; 32():34. PubMed ID: 29202426
    [No Abstract]   [Full Text] [Related]  

  • 34. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring treatment and managing adherence in schizophrenia.
    Marder SR
    J Clin Psychiatry; 2013 Oct; 74(10):e21. PubMed ID: 24229761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa-McMillan A
    J Clin Psychiatry; 2012 Sep; 73(9):1224-33. PubMed ID: 22938760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].
    Schanda H; Stompe T
    Neuropsychiatr; 2010; 24(1):14-26. PubMed ID: 20146916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing the stigma of long acting injectable antipsychotics - current concepts and future developments.
    Taylor DM; Velaga S; Werneke U
    Nord J Psychiatry; 2018 Sep; 72(sup1):S36-S39. PubMed ID: 30688170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
    Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
    J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How study designs influence comparative effectiveness outcomes: the case of oral versus long-acting injectable antipsychotic treatments for schizophrenia.
    Alphs L; Schooler N; Lauriello J
    Schizophr Res; 2014 Jul; 156(2-3):228-32. PubMed ID: 24842538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.